Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
D ThaçiKim A PappD MarcouxL WeibelA PinterP-D GhislainI LandellsPeter H HoegerK UnnebrinkM M B SeygerD A WilliamsS RubantS PhilippPublished in: The British journal of dermatology (2019)
After 52 weeks of long-term ADA treatment in children aged 4-18 years with severe plaque psoriasis, disease severity was reduced and maintained or further improved, as demonstrated by efficacy outcomes. No new safety risks were identified. What's already known about this topic? The results from the first three periods of this phase III trial in children aged 4-18 years with severe plaque psoriasis suggest that adalimumab is a safe and efficacious treatment option in this population. What does this study add? This is the first study to evaluate long-term treatment of adalimumab in children with severe psoriasis, and the first to evaluate switching from methotrexate to adalimumab in this population.
Keyphrases
- phase iii
- clinical trial
- double blind
- open label
- rheumatoid arthritis
- young adults
- phase ii
- placebo controlled
- early onset
- coronary artery disease
- emergency department
- juvenile idiopathic arthritis
- study protocol
- systemic lupus erythematosus
- metabolic syndrome
- randomized controlled trial
- risk assessment
- adipose tissue
- weight loss
- insulin resistance
- disease activity